Shares of NantHealth Inc (NYSE:NH) have been assigned a consensus rating of “Buy” from the six analysts that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $8.55.

NH has been the topic of several recent analyst reports. Jefferies Group LLC reaffirmed a “buy” rating and set a $5.50 price target (down previously from $8.00) on shares of NantHealth in a research report on Monday, June 19th. Canaccord Genuity reaffirmed a “buy” rating and set a $6.00 price target (down previously from $8.00) on shares of NantHealth in a research report on Monday, August 21st. Finally, BidaskClub raised NantHealth from a “strong sell” rating to a “sell” rating in a research report on Friday.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in shares of NantHealth by 20.2% during the 2nd quarter. Vanguard Group Inc. now owns 423,537 shares of the company’s stock worth $1,792,000 after acquiring an additional 71,087 shares during the period. Highbridge Capital Management LLC bought a new position in shares of NantHealth during the 1st quarter worth approximately $998,000. Goldman Sachs Group Inc. boosted its stake in shares of NantHealth by 91.5% during the 2nd quarter. Goldman Sachs Group Inc. now owns 169,603 shares of the company’s stock worth $717,000 after acquiring an additional 81,024 shares during the period. Northern Trust Corp boosted its stake in shares of NantHealth by 133.9% during the 2nd quarter. Northern Trust Corp now owns 151,907 shares of the company’s stock worth $643,000 after acquiring an additional 86,955 shares during the period. Finally, State Street Corp boosted its stake in shares of NantHealth by 88.1% during the 2nd quarter. State Street Corp now owns 147,234 shares of the company’s stock worth $623,000 after acquiring an additional 68,963 shares during the period.

Shares of NantHealth (NYSE:NH) traded up 3.298% during midday trading on Friday, reaching $3.915. The company’s stock had a trading volume of 79,018 shares. The firm’s market cap is $477.42 million. NantHealth has a 12 month low of $2.60 and a 12 month high of $15.80. The company has a 50-day moving average price of $3.60 and a 200-day moving average price of $4.13.

NantHealth (NYSE:NH) last posted its quarterly earnings results on Thursday, August 10th. The company reported ($0.58) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by $0.32. The company had revenue of $26.23 million for the quarter, compared to analyst estimates of $31.28 million. NantHealth had a negative return on equity of 83.97% and a negative net margin of 267.11%. The firm’s revenue for the quarter was down 16.7% compared to the same quarter last year. During the same period last year, the firm earned ($0.15) EPS. Equities analysts expect that NantHealth will post ($0.70) earnings per share for the current year.

WARNING: “NantHealth Inc (NH) Given Average Rating of “Buy” by Brokerages” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.americanbankingnews.com/2017/09/08/nanthealth-inc-nh-given-average-rating-of-buy-by-brokerages.html.

About NantHealth

NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.

Receive News & Ratings for NantHealth Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth Inc and related companies with MarketBeat.com's FREE daily email newsletter.